KYTX fundamentals
An in-depth look to Kyverna Therapeutics, Inc. operating, investing, and financing activities
KYTX free cash flow for Q3 24 is -27.59 M USD. For 2023, KYTX free cash flow was -53.03 M USD and operating cash flow was -52.41 M USD.
Q4 '22
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q4 '22
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM